

# 19th Annual Wealth Creation Study 2009-2014

# 100x

The power of growth in Wealth Creation

By Raamdeo Agrawal

**12 December 2014** 



# 100x

The power of growth in Wealth Creation

# **Theme Discussion Points**



- **□ 100x**: What & Why
- □ 100x: The Indian experience (1994-2014)
- **□** 100x: Alchemy of SQGLP
- 100x: How to apply for the future

# **Powerful mantra for big Wealth Creation**



# To make money in stocks you must have -

- > the <u>vision</u> to see them
- the courage to buy them and
- the <u>patience</u> to hold them.

# Patience is the rarest of the three.

- Thomas Phelps in 100 to 1 In The Stock Market

# What is 100x?




- "100x" refers to stock prices rising 100-fold over time
- The exact number "100" is not so important
- What is important is –
   100x opens the mind to the power of long-term compounding in equity investing





# **Understanding the Time-Rate combination for 100x**



# Why 100x?



# Warren Buffett on investing and purchasing power


"Investing is often described as the process of laying out money now in the expectation of receiving more money in the future.

At Berkshire Hathaway we take a more demanding approach, defining investing as the transfer to others of purchasing power now with the reasoned expectation of receiving more purchasing power in the future – net of taxes on nominal gains and inflation."

# Why 100x?




# 100x enables accumulation of massive purchasing power







# **Indian benchmark indices rise 100x in 30 years**



## **100x – The Indian Experience**



# Two kinds of 100x stocks in last 20 years (1994-2014):

### 1. TRANSITORY

- mainly fads and cyclicals which fizzled out after rising 100x
- Satyam Computer, SSI, Unitech, Jai Corp, Mercator, etc

### 2. ENDURING

- meaningful size and scale of operations
- saw stock prices rise 100x or more during the period
- and most importantly, maintained their 100x status even as of March 2014 (financial year-end)

# **100x – The Indian Experience**



# 47 enduring 100x stocks over 1994-2014


Company	Price	Year of	Company	Price	Year of	Company	Price	Year of
	Mult. (x)	purchase		Mult. (x)	purchase		Mult. (x)	purchase
Infosys	2,902	1994	Glenmark Pharma	299	2000	Ipca Labs	150	2002
Lupin	1,170	2002	Hindustan Zinc	298	1997	NMDC	145	2003
Wipro	875	1994	CMC	277	1997	Gujarat Fluorochem	145	1994
Motherson Sumi	775	1999	KPIT Tech	247	2002	Ajanta Pharma	142	2004
Shree Cement	644	1998	Symphony	245	2009	Dr Reddy's Labs	140	1994
Kotak Mahindra	608	2000	TTK Prestige	233	2005	Coromandel Inter	139	1997
Emami	544	1996	Titan Company	232	2002	Berger Paints	137	1997
Vakrangee	525	2000	Cipla	222	1994	Shriram Transport	135	2002
Eicher Motors	452	2000	Hero MotoCorp	216	1994	CRISIL	127	1996
Aurobindo Pharma	452	1997	GRUH Finance	203	2002	United Breweries	125	2003
Blue Dart Express	417	1999	MphasiS	199	1995	Axis Bank	119	2000
Havells India	372	2000	Sesa Sterlite	196	2001	Crompton Greaves	118	1998
Amara Raja	368	1995	Godrej Inds	164	2002	Pidilite Inds	109	1994
Sun Pharma	347	1997	Jindal Steel	158	2002	Alstom T&D India	107	2002
P I Inds	343	2005	HDFC Bank	156	1996	Asian Paints	106	1994
Balkrishna Inds	310	1994	Supreme Inds	155	2002			_

Note: Multiples are based on stocks being bought at the low price for the respective year, and held on to Mar-2014.





# 100x in 12 years (47% CAGR); interim returns healthy





- S Size
- **Q** Quality
- **G** Growth
- L Longevity
- P Price



# S - Size

**Small & relatively unknown** (at the time of purchase)

- Small, both in Mkt Cap and Sales
  - 47 stocks: Avg revenue Rs 300 cr, mcap Rs 250 cr
- Relatively unknown
  - low institutional holding, analyst coverage, volumes



# **Q** – Quality

# **High quality business X High quality management**

# Quality business

- Large profit pool
- Value Migration (IT, Pharma, Private banking)
- Niche / Strategic opportunity (Eicher, GPPL)
- Dominant market share (Pidilite, United Spirits)
- Economic Moat (Bosch)
- Favourable demand-supply (especially for commodities)



# **Q** – Quality


**High quality business X High quality management** 

- Quality management
  - Integrity
  - Competence
  - Growth mindset




# **G** – Growth

# **Earnings Growth X Valuation Growth**





# **Quality v/s Growth**






# **L** – Longevity

# **Longevity of quality & Longevity of growth**

- Extend CAP (Competitive Advantage Period)
- Delay mean reversion of growth





# P - Price

### **Favourable valuation**

- Valuation growth lowers burden on Earnings growth for 100x
- Low P/E preferable; but not the only criterion

In the Bible, it says that love covers a multitude of sins.

Well, in the investing field, price covers a multitude of mistakes.

For human beings, there is no substitute for love.

For investing there is no substitute for paying the right price – absolutely none.

— Van Den Berg, Outstanding Investor Digest, April 2004





# Relatively objective criteria to hunt for

- Market cap < 3,000 crores (\$0.5 billion)</li>
- Likely beneficiary of Value Migration / Niche opportunity
- P/E less than 25x

### IMPORTANT NOTE

- The companies mentioned here should not be construed as our investment recommendations.
- Assessing quality of management is subjective, requires a high level of due diligence, and not in the scope of this study.



# **STATUTORY WARNING!!**

Investing blindly on others' recommendation may be highly injurious to wealth!





# **Companies which meet the objective criteria for 100x**

Small, unknown	Value Migration /	P/E	
(Mkt Cap, Rs cr)	Niche opportunity		
10	Pharma exports	13	
22	Pharma exports	17	
16	Pharma exports	17	
29	Private banking	18	
19	Software exports	21	
20	Oncology drugs research	24	
10	Niche 3-wheeler player	25	
	(Mkt Cap, Rs cr)  10  22  16  29  19  20	(Mkt Cap, Rs cr) Niche opportunity  10 Pharma exports  22 Pharma exports  16 Pharma exports  29 Private banking  19 Software exports  20 Oncology drugs research	



# Thank You! & Happy Investing For

100x1

### **IMPORTANT DISCLAIMER**

- This study is primarily an analysis of economic data, company financials and stock prices.
- The companies mentioned here should not be construed as our investment recommendations or opinions.